Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa.

Abstract

BACKGROUND:

Trials demonstrating the efficacy of biologic therapy for moderate to severe hidradenitis suppurativa (HS) have inspired new multidisciplinary treatment strategies. We present our experience with combined biologic and surgical therapy for recalcitrant HS.

METHODS:

Between 2011 and 2014, 21 patients (57 cases) with Hurley Stage III HS underwent radical resection with delayed primary closure alone, or in combination with adjuvant biologic therapy. Demographic data, treatment regimen, outcomes, and complications were retrospectively reviewed for all cases.

RESULTS:

Eleven patients underwent combined surgical and biologic therapy, whereas radical resection alone was performed in 10 patients. The average soft tissue deficit, before closure, for the combined and surgery-only patients was 56 cm and 48.5 cm, respectively (P = 0.66). Biologic agents including infliximab (n = 8) and ustekinumab (n = 3) were initiated 2 to 3 weeks after closure and were continued for an average of 10.5 months. Recurrence was noted in 19% (4/29) and 38.5% (10/26) of previously treated sites for combined and surgery-only patients (P < 0.01). For the combined cohort, the disease-free interval was approximately 1 year longer on average (P < 0.001); however, this difference was reduced to 4.5 months when considering time to recurrence after cessation of biologic therapy (P = 0.09). New disease developed in 18% (2/11) and 50% (5/10) of combined and surgery-only patients, respectively (P < 001). No adverse events were noted among patients who received biologic therapy.

CONCLUSIONS:

Lower rates of recurrence and disease progression, as well as a longer disease-free interval may be achieved with the use of adjuvant biologic therapy after radical resection for recalcitrant HS.

• Authors: Michael V DeFazio, James M Economides, Kathryn S King, Kevin D Han, Victoria K Shanmugam, Christopher E Attinger, Karen K Evans
• Journal: Annals of plastic surgery (Ann Plast Surg) Vol. 77 Issue 2 Pg. 217-22 (Aug 2016) ISSN: 1536-3708 [Electronic] United States
• PMID: 26559649 (Publication Type: Evaluation Study, Journal Article)

Chemical References

• Dermatologic Agents
• Infliximab
• Ustekinumab

Topics

• Adolescent
• Adult
• Aged
• Combined Modality Therapy
• Dermatologic Agents (therapeutic use)
• Dermatologic Surgical Procedures
• Disease Progression
• Female
• Follow-Up Studies
• Hidradenitis Suppurativa (therapy)
• Humans
• Infliximab (therapeutic use)
• Male
• Middle Aged
• Recurrence
• Retrospective Studies
• Treatment Outcome
• Ustekinumab (therapeutic use)
• Young Adult